Chinook Therapeutics, Inc.

罗森律师事务所宣布一项代表Chinook Therapeutics, Inc. (NASDAQ: KDNY) 的投资人对该公司潜在的集体诉讼请求发起调查。该调查缘起于对Chinook 可能向投资公众发布了具有重大误导性的商业信息的指控。

如果您购买了Chinook 股票,并且您想参加此次集体诉讼的话,请点击“加入此集体行动”键。


如果您购买了 Chinook 证券,您可能有权获得赔偿,而无需支付任何自付费用或通过应急费用安排产生的费用。

Details of investigation:

2023 年 5 月 16 日,Muddy Waters Research 发布了一份关于 Chinook Therapeutics, Inc. 的报告,称该公司的主要候选产品 atrasentan “已被证明对患者的心血管健康有害”,并且 “AbbVie 和 Chinook 似乎系统地操纵关于 atrasentan 的研究结果和介绍,为了掩盖试验结果。”

本消息导致Chinook Therapeutics 股票在 2023 年 5 月 16 日的盘中交易中下跌超过 7%。

Follow us on:
Company Name: Chinook Therapeutics, Inc.
Stock Symbol: KDNY
Class Period: N/A
Court: N/A

Why Rosen Law

The Rosen Law Firm has been ranked among the top 4 law firms each year since 2013 for the number of successful securities class actions on behalf of investors. In 2019 alone, our firm recovered $438 million for investors.

Investors should carefully identify and select experienced counsel with a track record of success leading securities class actions. Often other firms issue press releases about class actions yet do not have comparable experience or resources.

Institutional Shareholders Services ranked the Rosen Law Firm # 1 for the number of securities class action recoveries in 2017.

The Rosen Law Firm represents investors throughout the globe. Our mission is to prosecute securities fraud class actions and protect shareholders’ rights.

Scroll to Top